Low-dose CT lung cancer screening was most beneficial in the 60 percent of people who had the highest likelihood of dying from the disease.
Screening for lung cancer with low-dose computed tomography (CT) was the most beneficial in people who had the highest likelihood of dying from the disease, according to data taken from participants in the National Lung Screening Trial (NLST).
In fact, 88 percent of the deaths prevented by screening were among the 60 percent of participants classified as being at the highest risk for lung-cancer death using predictors including demographic and clinical risk factors for the disease.
“The findings provide evidence for outside organizations who are interested in developing risk-based lung screening recommendations,” Hormud A. Katki, PhD, from the division of cancer epidemiology and genetics at the National Cancer Institute, told Diagnostic Imaging. Katki and colleagues published the findings in The New England Journal of Medicine.
Current data show that lung cancer is the most common cause of cancer-related death in the United States, accounting for more than 25 percent of all cancer deaths. Previously published data from the NLST indicated that low-dose CT screening reduced lung cancer death among a population of heavy smokers.
“We wanted to determine which participants in the NLST might receive the greatest benefit from screening,” Katki said. “To do this, we calculated each NLST participant’s risk of lung cancer death in the NLST. We then calculated the number of prevented lung cancer deaths from LDCT lung screening.”
Katki and colleagues calculated the number of false positive results and lung-cancer deaths prevented among the 26,604 participants in the trial who underwent screening with CT. The participants were then placed into quintiles of five-year lung cancer death risk.
“Not surprisingly, we found that smokers with the highest risk of lung cancer had the most benefit from low-dose CT,” Katki said.
With each increasing risk quintile, the number of prevented lung cancer deaths per 10,000 person-years increased, from 0.2 in the lowest risk quintile to 12 in the highest quintile. When the researchers calculated a ratio of the number of participants with false positive results to the number of screening-prevented deaths, they found that the number decreased across risk quintiles with 1,648 for the lowest risk quintile and 65 for the highest risk quintile.
Only 1 percent of low-dose CT prevented lung-cancer deaths occurred among the 20 percent of participants who were at lowest risk.
“Although there is currently a consensus among published screening guidelines on recommending low-dose CT screening for patients who meet the NLST entry criteria, some experts have speculated that further refinement of selection criteria may be appropriate,” Katki and colleagues wrote. “Our results confirm that tailoring of low-dose CT screening to a patient’s predicted risk of lung-cancer death could narrow the NLST-eligible population without a loss in the potential public health benefits of screening or a disproportionate increase in the potential harms.”
The researchers specified that the results of this study must be interpreted within the context of using low-dose CT in the NLST. In addition, they acknowledge that this study did not take into account other potential harms of CT screening including “psychological burden of false positive results, complications with invasive follow-up procedures, and radiation-induced cancers.”
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.